Claims
- 1. A pharmaceutical composition comprising 0.5 mg to 5,000 mg of a sulfonium compound of the Formula (I) ##STR410## wherein R.sub.1 and R.sub.2 are each alkyl, cycloalkyl, cycloporpylmethyl, alkylene-2-tetrahydrofuranyl, alkylene-2-tetrahydropyranyl, alkenyl, phenyl which may be substituted with aklyl, alkoxy or halogen, aralkyl which may be substituted with alkyl, alkoxy or halogen on the benzene ring, or benzoyloxyethyl, Y.sub.1 is halogen, or an inorganic acid residue or organic acid residue, n is 1 or 2, and m is an integer of 1 to 15, together with a pharmaceutically acceptable carrier therefor.
- 2. Composition of claim 1, wherein m is an integer of 1 to 5.
- 3. Composition of claim 1, wherein one of R.sub.1 and R.sub.2 is alkyl.
- 4. Composition of claim 1, wherein R.sub.1 and R.sub.2 are each alkyl.
- 5. Composition of claim 4, wherein R.sub.1 and R.sub.2 are each methyl.
- 6. Composition as defined in claim 1, wherein Y.sub.1 is an organic sulfonic acid residue, an organic carboxylic acid residue or halogen.
- 7. Composition as defined in claim 6, wherein the organic sulfonic acid is toluenesulfonic acid, picrylsulfonic acid, cyclohexylsulfamic acid or methanesulfonic acid.
- 8. Composition as defined in claim 6, wherein the organic carboxylic acid is an unsaturated dibasic acid.
- 9. Composition as defined in claim 1, wherein R.sub.1 and R.sub.2 are each alkyl, m is an integer of 1 to 5, and Y.sub.1 is an organic sulfonic acid residue.
- 10. A method for stimulating the immune response in a mammal, said method comprising administering to said mammal an immunity stimulating effective amount of a sulfonium compound of the formula (I) ##STR411## wherein R.sub.1 and R.sub.2 are each alkyl, cycloalkyl, cyclopropylmethyl, alkylene-2-tetrahydrofuranyl, alkylene-2-tetrahydropyranyl, alkenyl, phenyl which may be substituted with alkyl, alkoxy or halogen, aralkyl which may be substituted with alkyl, alkoxy or halogen on the benzene ring, or benzoyloxyethyl, Y.sub.1 is halogen, or an inorganic acid residue or organic acid residue, n is 1 or 2, and m is an integer of 1 to 15, together with a pharmaceutically acceptable carrier therefor.
- 11. Method of claim 10, wherein m is an integer of 1 to 5.
- 12. Method of claim 10, wherein one of R.sub.1 and R.sub.2 is alkyl.
- 13. Method of claim 10, wherein R.sub.1 and R.sub.2 are each alkyl.
- 14. Method of claim 10, wherein R.sub.1 and R.sub.2 are each methyl.
- 15. Method of claim 10, wherein Y.sub.1 is an organic sulfonic acid residue, an organic carboxylic acid residue or halogen.
- 16. Method as defined in claim 15, wherein the organic sulfonic acid is toluenesulfonic acid, picrylsulfonic acid, cyclohexylsulfamic acid or methanesulfonic acid.
- 17. Method as defined in claim 15, wherein the organic carboxylic acid is an unsaturated dibasic acid.
- 18. Method as defined in claim 10, wherein R.sub.1 and R.sub.2 are each alkyl, m is an integer of 1 to 5, and Y.sub.1 is an organic sulfonic acid residue.
Priority Claims (2)
Number |
Date |
Country |
Kind |
55-18385 |
Feb 1980 |
JPX |
|
56-8500 |
Jan 1981 |
JPX |
|
Parent Case Info
This application is a continuation application of Ser. No. 343,293, filed Jan. 27, 1982, now abandoned, which is a divisional application of Ser. No. 231,126, filed Feb. 3, 1981, now U.S. Pat. No. 4,340,543.
US Referenced Citations (2)
Number |
Name |
Date |
Kind |
2562042 |
Kipnis |
Jul 1951 |
|
3455956 |
Hirano et al. |
Jul 1969 |
|
Non-Patent Literature Citations (1)
Entry |
Rutter, Jr., JACS, 73, 5905 (1951). |
Divisions (1)
|
Number |
Date |
Country |
Parent |
231126 |
Feb 1981 |
|
Continuations (1)
|
Number |
Date |
Country |
Parent |
343293 |
Jan 1982 |
|